Global News

Genocea releases positive results for genital herpes treatment GEN-003

Tuesday, April 5, 2016

Genocea Biosciences, a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, has announced positive 12 month efficacy data from its phase II dose optimization trial evaluating GEN-003 for the treatment of genital herpes. GEN-003 demonstrated sustained and statistically significant reductions compared to baseline in the rate of viral shedding 12 months after dosing across multiple dose groups as well as sustained efficacy at multiple dose levels across secondary endpoints measuring the impact on clinical disease. GEN-003 was safe and well-tolerated by patients, with no serious adverse events related to the vaccine in the trial.

[Read More]

HealthCarePoint launches BlueCloud 2.0 networking technology

Tuesday, April 5, 2016

HealthCarePoint (HCP), a Texas-based healthcare and clinical research networking-technology company founded by patient survivors, has successfully completed global testing of its BlueCloud business model and networking technology and unveiled BlueCloud 2.0. In the past year, thousands of healthcare and clinical research organizations and other stakeholders have connected with BlueCloud 2.0 to help innovate its private, secure and verifiable network.

[Read More]

FEI partners to form Cryo-EM research consortium

Tuesday, April 5, 2016

FEI has partnered to form the “Cambridge Pharmaceutical Cryo-EM Consortium.” Partners include five pharmaceutical companies—Astex Pharmaceuticals, AstraZeneca, GlaxoSmithKline, Heptares Therapeutics and UCB; the Medical Research Council Laboratory of Molecular Biology (MRC-LMB); and the University of Cambridge’s Nanoscience Center. As part of the three-year agreement, FEI will provide sample preparation and data collection services on a Titan Krios cryo-transmission electron microscope (cryo-EM) to the consortium companies for early-stage drug discovery research.

[Read More]

Report: Slowest quarter for venture-backed IPOs since 2011

Tuesday, April 5, 2016

Six venture-backed initial public offerings (IPOs) raised $574.5 million in the first quarter of 2016, according to the Exit Poll Report by Thomson Reuters and the National Venture Capital Association (NVCA). This marks the slowest quarter for venture-backed IPOs since the third quarter of 2011. By merger and acquisition (M&A), 79 venture-backed M&A deals were reported in the first quarter, 20 of which reported an aggregate deal value of $4.8 billion.   

[Read More]

Dotmatics, BioByte partner to speed drug candidate selection

Tuesday, April 5, 2016

Dotmatics, a provider of scientific informatics solutions and services to the life sciences industry, announced a partnership with BioByte, producer of the industry gold standard partition coefficient calculator (ClogP). This deal will enable users of the Dotmatics Platform including Vortex and Browser to calculate ClogP seamlessly within the applications. This will streamline the research process and speed up the selection of potential drug candidates.  

[Read More]

Getting the most from a central advertising campaign

Monday, April 4, 2016

The Pulse on Patient Recruitment by Ashley Tointon

There are few Patient Recruitment and Retention (PRR) tactics that are more controversial than the central advertising campaign. Although central advertising can cover several different mediums such as television, print, radio and online, most users fall into one of two groups: the “it worked” group or the “it didn’t work” group. This dichotomy is pronounced regardless of factors unique to each clinical trial, and hamper efforts to broaden the use of advertising for clinical trials. There are many factors that drive these strong opinions, including cost, the communication of expectations and the accountability of the study sites.

[Read More]